BLA 210089 · Cis Bio Intl
Pulmotech Maa
Technetium Tc99m Albumin Aggregated · Injection
Last checked: Nov 20, 2026Latest source record: Aug 25, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Mar 20, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
0 Phase 3, 0 recruiting
FAERS reports
3
1 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 13, 2025.
PULMOTECH MAA, after radiolabeling with technetium-99m, is indicated for: Lung scintigraphy as an adjunct in the evaluation of pulmonary perfusion in adults and pediatric patients. Peritoneovenous shunt scintigraphy as an aid in the evaluation of its patency in adults. PULMOTECH MAA, after radiolabeling with technetium-99m is a radioactive diagnostic agent indicated for: Lung scintigraphy as an adjunct in the evaluation of pulmonary perfusion in adults and pediatric patients. ( 1 ) Peritoneovenous shunt scintigraphy as an aid in the evaluation of its patency in adults. ( 1 )
Mechanism: Within 1 to 5 minutes of intravenous injection, over 90 percent of the technetium Tc 99m albumin aggregated particles are trapped in the arterioles and capillaries of the lung. Following intraperitoneal administration, technetium Tc 99m albumin aggregated mixes with the peritoneal fluid. Clearance from the peritoneal cavity varies from insignificant, which may occur with complete shunt blockage, to very rapid clearance with subsequent transfer into the systemic circulation when the shunt is patent.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- PULMOTECH MAA · TECHNETIUM TC99M ALBUMIN AGGREGATED 2MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Technetium Tc99m Albumin Aggregated" as an intervention, any sponsor and status, largest first.
University of WashingtonAcademic, hospital or other
NCT01982123 · 12 participants · Start Jan 17, 2014 · Primary completion Sep 13, 2017
Drug: Technetium Tc-99m DTPA · For: Lung Carcinoma; Malignant Neoplasm
Sites: Seattle, Washington · 2 sites in all
- ThoHSpEkt Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With Free-hand SPECTTerminated
Cantonal Hospital of St. GallenAcademic, hospital or other
NCT02050724 · 11 participants · Start Nov 2013 · Primary completion Dec 31, 2016
Drug: Radioactive labelling of pulmonary nodules · For: Solitary Pulmonary Nodule; Bronchial Neoplasms
Sites: Sankt Gallen, Switzerland
Massachusetts General HospitalAcademic, hospital or other
NCT04105283 · 8 participants · Start Aug 1, 2020 · Primary completion Jun 1, 2024
Drug: Tc99m-MAA · For: Lung Cancer
Sites: Boston, Massachusetts
Sirtex MedicalIndustry
NCT05848947 · 5 participants · Start Apr 25, 2023 · Primary completion Jul 5, 2023
Drug: 99mTc-Macro Albumin Aggregate · For: Carcinoma; Carcinoma, Hepatocellular; Liver Neoplasm
Sites: Spokane, Washington
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dizziness1
- muscular weakness1
- product preparation error1
- radioisotope scan abnormal1
- syncope1
- ventilation/perfusion scan abnormal1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 2 |
| 2024 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Cis Bio Intl
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.